Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
MASI completes sale of Sound United to HARMAN, sharpening focus on core healthcare, boosting margins, and funding buybacks.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Masimo (MASI) could produce exceptional returns because of its solid growth attributes.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Medical monitoring technology company Masimo sued U.S. Customs and Border Protection on Wednesday over a decision by the agency that allowed Apple to import Apple Watches with blood-oxygen reading technology during a patent dispute between the companies.
MASI gains FDA clearance to expand O3 monitoring with delta hemoglobin parameters across all patient groups.
Masimo (MASI) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Masimo's second-quarter 2025 performance beats earnings and revenue estimates, expands margins and lifts 2025 outlook.
Masimo Corporation (NASDAQ:MASI ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants Catherine M. Szyman - CEO & Director Eli Kammerman - Vice President of Business Development & Investor Relations Micah Young - Chief Financial Officer Conference Call Participants Frederick Allen Wise - Stifel, Nicolaus & Company, Incorporated, Research Division Jason M.
Masimo (MASI) came out with quarterly earnings of $1.33 per share, beating the Zacks Consensus Estimate of $1.23 per share. This compares to earnings of $0.86 per share a year ago.
Masimo (MASI) could produce exceptional returns because of its solid growth attributes.